<DOC>
	<DOCNO>NCT01561794</DOCNO>
	<brief_summary>The main objective study investigate safety , pharmacokinetics ( PK ) relationship PK pharmacodynamics ( Minimum Inhibitory Concentration [ MIC ] Mutant Prevention Concentration [ MPC ] ) intravenous BAYQ3939 ( 400 mg BID 400 mg TID ) hospitalize patient bacterial pneumonia secondary infection chronic respiratory disease severe disease poor response antimicrobial . In addition , efficacy ciprofloxacin , term clinical response microbiological response , investigate , secondary endpoint .</brief_summary>
	<brief_title>A Phase III Study Evaluate Safety , Efficacy Pharmacokinetics/Pharmacodynamics BAYQ3939 Patients With Bacterial Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Males nonpregnant , nonlactating female write informed consent , 20 year age older . Within 48 hour prior first study drug administration , patient pathogens identified appropriate specimen ( e.g. , sputum , tracheal aspirate , bronchoalveolar lavage [ BAL ] , protect brush specimen [ PBS ] ) , appropriate specimen highly likely identify pathogen sample . ( However , patient Legionellosis enrol test Legionella antigen positive . ) The follow severe bacterial pneumonia meeting diagnostic criterion pneumonia secondary infection chronic respiratory disease Severe pneumonia Communityacquired pneumonia : PORT score III , IV V Hospitalacquired pneumonia [ HAP ] Group B low risk multidrugresistant pathogens Patients [ HAP ] Group A whose pathogen suspect Pseudomonas aeruginosa Hospitalized patient bacterial pneumonia poor response antimicrobial Note : The patient limited CAP patient PORT score III , IV V HAP patient withGroup A B n't respond poor response antimicrobials 3day 's treatment.2 Secondary infection chronic respiratory disease Patients hospitalize treatment secondary infection chronic respiratory disease Hospitalized patient secondary infection chronic respiratory disease poor response antimicrobial Note : The patient limit secondary infection chronic respiratory disease patient n't respond poor response antimicrobials 3day 's treatment . Creatinine clearance ( Ccr ) â‰¤ 30 mL/min nephrotic syndrome Patient chronic treatment immunosuppressive drug Decompensated congestive heart failure Subject receive 24 hour antibacterial drug current infection Patient require Intensive Care Unit ( ICU ) management [ In case subject n't correspond severity ICU management need admit ICU due circumstance site ( e.g . shortage hospital bed ) , subject shall exclude ] Patients infection pneumonia secondary infection chronic pulmonary disease Lung abscess , empyema Viral , fungal , mycobacterial , atypical pneumonia primary diagnosis Known suspect bacteremia secondary Staphylococcus aureus Known causative microorganism indication ( microorganism ) study drug , positive urinary antigen test Streptococcus pneumonia Infection necessitate use concomitant antibacterial agent addition study medication [ exclude subject concomitant use longterm , lowdose macrolide chronic respiratory disease , sulbactam sodium/ampicillin sodium ( UnasynS ) clindamycin ( DalacinS ) ] Known bronchial obstruction history postobstructive pneumonia Known primary lung cancer</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Ciprofloxacin</keyword>
	<keyword>Bacterial pneumonia</keyword>
	<keyword>Community Acquired Pneumonia ( CAP )</keyword>
	<keyword>Hospital Acquired Pneumonia ( HAP )</keyword>
	<keyword>Secondary infection chronic respiratory disease</keyword>
	<keyword>400 mg BID/TID</keyword>
</DOC>